The arrival of Retatrutide ZPHC, at a strength of 120mg, is creating considerable buzz within the healthcare community. This novel dual GIP and GLP-1 agonist medication seems to deliver notable improvements in fat reduction compared to previous therapies. Initial clinical data have indicated sign